In summary PTCT has a good prognosis with the 5-year overall survival rate of 78.7% and the 5-year specific survival rate of 84.3% and should be alternatively considered in Cdx-2 positive metastatic tumor of unknown origin [19]. This evidence concerns the gene CDX2 and metastatic neoplasm.